Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
pubmed:
17
10
2018
medline:
29
1
2020
entrez:
17
10
2018
Statut:
ppublish
Résumé
Persons living with HIV (PLWH) well treated on antiretroviral therapies remain at risk for ensuing arterial disease. We investigated the relationship between adipose depots and biomarkers of arterial injury and inflammation to gain insight into the link between body composition and CVD risk. One hundred and fifty-five HIV-infected and 70 non-HIV infected individuals were well phenotyped for body composition. Adipose depots were assessed via single-slice abdominal computed tomography (CT). Circulating markers of arterial disease and generalized inflammation [lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), high-sensitivity cardiac troponin T (hs-cTnT), high-sensitivity C-reactive protein (hsCRP)] were evaluated. Despite similar BMI and visceral adipose tissue (VAT), HIV-infected individuals had significantly lower subcutaneous adipose tissue [SAT, 199 (126-288) vs. 239 (148-358) cm(2), P = 0.04] than non-HIV infected individuals. Among HIV-infected individuals, reduced SAT inversely correlated with LpPLA2 (ρ = -0.19, P = 0.02) and hs-cTnT (ρ = -0.24, P = 0.004), whereas increased VAT significantly and positively related to LpPLA2 (ρ = 0.25, P = 0.003), oxLDL (ρ = 0.28, P = 0.0005), hs-cTnT (ρ = 0.28, P = 0.0007) and hsCRP (ρ = 0.32, P = < 0.0001). Similar analyses among the non-HIV infected individuals revealed significant relationships between SAT and LpPLA2 (ρ = -0.24, P = 0.05), as well as VAT and LpPLA2 (ρ = 0.37, P = 0.002), oxLDL (ρ = 0.24, P = 0.05) and hsCRP (ρ = 0.29, P = .02). In modelling performed among the HIV group, simultaneously controlling for VAT, SAT, age and relevant HIV-related parameters, reduced SAT was an independent predictor of LpPLA2 (P = 0.04) and hs-cTnT (P = 0.005) and increased VAT was an independent predictor of LpPLA2 (P = 0.001), oxLDL (P = 0.02), hs-cTnT (P = 0.04) and hsCRP (P = 0.04). Fat redistribution phenotypes, characterized by SAT loss and/or VAT accumulation, may be linked to arterial injury and inflammation in HIV.
Identifiants
pubmed: 30325779
doi: 10.1097/QAD.0000000000002060
pmc: PMC6311412
mid: NIHMS999599
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT00455793']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-236Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL092792
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR001066
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001102
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025758
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL136262
Pays : United States
Références
Trends Mol Med. 2010 May;16(5):218-29
pubmed: 20400373
HIV Clin Trials. 2006 Mar-Apr;7(2):41-7
pubmed: 16798618
Diabetologia. 2018 May;61(5):1155-1166
pubmed: 29427237
J Infect Dis. 2013 Dec 1;208(11):1737-46
pubmed: 24041790
Open Forum Infect Dis. 2016 Jun 16;3(2):ofw098
pubmed: 27419170
JAMA Cardiol. 2016 Jul 1;1(4):474-80
pubmed: 27438325
JCI Insight. 2017 Oct 19;2(20):
pubmed: 29046481
Lipids Health Dis. 2013 Feb 15;12:19
pubmed: 23413990
J Am Coll Cardiol. 2006 Nov 7;48(9):1818-24
pubmed: 17084256
Circulation. 2013 Aug 20;128(8):814-22
pubmed: 23817574
J Am Heart Assoc. 2018 Mar 3;7(5):
pubmed: 29502100
JAMA Intern Med. 2013 May 13;173(9):763-9
pubmed: 23568589
AIDS. 2016 Sep 10;30(14):2205-14
pubmed: 27314177
JACC Heart Fail. 2014 Dec;2(6):600-7
pubmed: 25443112
Curr HIV/AIDS Rep. 2017 Jun;14(3):93-100
pubmed: 28434169
AIDS. 2008 Sep;22 Suppl 3:S19-26
pubmed: 18845918
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):151-9
pubmed: 24091690
J Am Coll Cardiol. 2013 Sep 3;62(10):921-5
pubmed: 23850922
AIDS. 2010 Jan 16;24(2):243-53
pubmed: 19996940
Clin Infect Dis. 2014 Mar;58(6):893-900
pubmed: 24336757
PLoS Pathog. 2015 Sep 24;11(9):e1005153
pubmed: 26402858
J Infect Dis. 2011 Oct 15;204(8):1227-36
pubmed: 21917896
Circulation. 2007 Sep 11;116(11):1234-41
pubmed: 17709633
Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2523-9
pubmed: 16960105
AIDS. 2015 Mar 27;29(6):667-74
pubmed: 25849830
Int J Obes (Lond). 2006 Nov;30(11):1615-22
pubmed: 16534517
N Engl J Med. 2009 Dec 24;361(26):2538-47
pubmed: 19940289
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004043
pubmed: 27072302
Clin Infect Dis. 2011 Jul 15;53(2):185-96
pubmed: 21690627
Circulation. 2007 May 29;115(21):2715-21
pubmed: 17502572
J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):308-316
pubmed: 29210836
Antivir Ther. 2013;18(2):243-8
pubmed: 23041595
JAMA. 2012 Jul 25;308(4):379-86
pubmed: 22820791
Circulation. 2015 Feb 10;131(6):528-35
pubmed: 25480813
Clin Infect Dis. 2016 Apr 1;62(7):853-62
pubmed: 26797215